Clinical Trial Update: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of ISB 1442 for relapsed/refractory multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ISB 1442

Snippet

Sponsor: Ichnos Sciences SA | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED